Clinical Value of Thyrotropin Receptor Antibodies for the Differential Diagnosis of Interferon Induced Thyroiditis

Abstract

Objective: The clinical value of thyrotropin receptor antibodies for the differential diagnosis of thyrotoxicosis induced by pegylated interferon-alpha remains unknown. We analyzed the diagnostic accuracy of thyrotropin receptor antibodies in the differential diagnosis of thyrotoxicosis in patients with chronic hepatitis C (CHC) receiving pegylated interferon-alpha plus ribavirin.

Methods: Retrospective analysis of 274 patients with CHC receiving pegylated interferon-alpha plus ribavirin. Interferon-induced thyrotoxicosis was classified according to clinical guidelines as Graves disease, autoimmune and non- autoimmune destructive thyroiditis.

Results: 48 (17.5%) patients developed hypothyroidism, 17 (6.2%) thyrotoxicosis (6 non- autoimmune destructive thyroiditis, 8 autoimmune destructive thyroiditis and 3 Graves disease) and 22 “de novo” thyrotropin receptor antibodies (all Graves disease, 2 of the 8 autoimmune destructive thyroiditis and 17 with normal thyroid function). The sensitivity and specificity of thyrotropin receptor antibodies for Graves disease diagnosis in patients with thyrotoxicosis were 100 and 85%, respectively. Patients with destructive thyroiditis developed hypothyroidism in 87.5% of autoimmune cases and in none of those with a non- autoimmune etiology (p<0.001).

Conclusion: Thyrotropin receptor antibodies determination cannot replace thyroid scintigraphy for the differential diagnosis of thyrotoxicosis in CHC patients treated with pegylated interferon.

Key words

Graves-disease - thyroid-stimulating immunoglobulins - interferon induced thyroiditis - pegylated interferon-alpha

• References

• 1 Goldstein D, Laszlo J. The role of interferon in cancer therapy: a current perspective. CA Cancer J Clin 1988; 38: 258-277
• 2 Hauschild A, Gogas H, Tarhini A et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 2008; 112: 982-994
• 3 Cooksley WG. The role of interferon therapy in hepatitis B. Med Gen Med 2004; 18: 16
• 4 Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
• 5 Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003; 124: 1711-1719
• 6 Mazziotti G, Sorvillo F, Stornaiuolo G et al. Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study. J Endocrinol Invest 2002; 25: 624-630
• 7 Andrade LJ, Atta AM, Atta ML et al. Thyroid disorders in patients with chronic hepatitis C using interferon-alpha and ribavirin therapy. Braz J Infect Dis 2011; 15: 377-381
• 8 Kim BK, Choi YS, Park YH et al. Interferon-alpha-induced destructive thyroiditis followed by Graves’ disease in a patient with chronic hepatitis C: a case report. J Korean Med Sci 2011; 26: 1638-1641
• 9 Wirth S, Pieper-Boustani H, Lang T et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005; 41: 1013-1018
• 10 Kee KM, Lee CM, Wang JH et al. Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis. J Gastroenterol Hepatol 2006; 21: 319-326
• 11 Gehring S, Kullmer U, Koeppelmann S et al. Prevalence of autoantibodies and the risk of autoimmune thyroid disease inchildren with chronic hepatitis C virus infection treated with interferon-alpha. World J Gastroenterol 2006; 28: 5787-5792
• 12 Huang JF, Chuang WL, Dai CY et al. The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-alpha and ribavirin combination therapy. J Viral Hepat 2006; 13: 396-401
• 13 Vasiliadis T, Anagnostis P, Nalmpantidis G et al. Thyroid dysfunction and long-term outcome during and after interferon alpha therapy in patients with chronic hepatitis C. Ann Acad Med Singapore 2011; 40: 394-400
• 14 Barut S, Gunal O, Erkorkmaz U et al. Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005–2010. Braz J Infect Dis 2012; 16: 448-451
• 15 Dabrowska MM, Panasiuk A, Flisiak R. Thyroid dysfunction in antiviral therapy of chronic hepatitis C. Hepatogastroenterol 2010; 57: 826-831
• 16 Mandac JC, Chaudhry S, Sherman KE et al. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology 2006; 43: 661-672
• 17 Mazziotti G, Sorvillo F, Piscopo M et al. Innate and acquired immune system in patients developing interferon alpha-related autoimmune thyroiditis: a prospective study. J Clin Endocrinol Metab 2005; 90: 4138-4144
• 18 Tozzoli R, Bagnasco M, Giavarina D et al. TSH receptor autoantibody immunoassay in patients with Graves' disease: improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis. Autoimmun Rev 2012; 12: 107-113
• 19 Ghany MG, Strader DB, Thomas DL et al American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49M: 1335-1374
• 20 Carrión JA, Gonzalez-Colominas E, García-Retortillo M et al. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C. J Hepatol 2013; 59: 926-933
• 21 Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293
• 22 Bahn Chair RS, Burch HB, Cooper DS et al American Thyroid Association; AmericanAssociation of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011; 21: 593-646
• 23 Pearce EN, Hennessey JV, McDermott MT. New American Thyroid Association and American Association of Clinical Endocrinologists guidelines for thyrotoxicosis and other forms of hyperthyroidism: significant progress for the clinician and a guide to future research. Thyroid 2011; 21: 573-576
• 24 Wong V, Fu AX, George J et al. Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin Endocrinol (Oxf) 2002; 56: 793-798
• 25 Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F et al. Increased risk of autoimmune thyroid disease in hepatitis C vs. hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med 1998; 158: 1445-1448
• 26 Roti E, Minelli R, Giuberti T et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alfa. Am J Med 1996; 101: 482-487
• 27 Carella C, Amato G, Biondi B et al. Longitudinal study of antibodies against thyroid in patients undergoing interferon-alpha therapy for HCV chronic hepatitis. Horm Res 1995; 44: 110-114
• 28 Baudin E, Marcellin P, Pouteau M et al. Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin Endocrinol (Oxf) 1993; 39: 657-661
• 29 Nair Kesavachandran C, Haamann F, Nienhaus A. Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients: a systematic review based analysis. PLoS One 2013; 8: 553-564